Loading...
•
Mar 31, 2021
PDS Biotechnology Q1 2021 Earnings Report
PDS Biotech reported a net loss and provided a business update.
Key Takeaways
PDS Biotech reported a net loss of $3.0 million for the first quarter of 2021, with a decrease in both research and development expenses and general and administrative expenses compared to the same period in 2020. The company's cash balance as of March 31, 2021, was approximately $25.0 million.
National Cancer Institute to present interim efficacy and safety data of PDS0101 Phase 2 clinical trial at ASCO 2021 Annual Meeting.
COVID-19 consortium received a commitment from the Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine by Farmacore in Brazil.
Net loss was approximately $3.0 million, or $0.14 per basic share and diluted share.
Cash balance as of March 31, 2021 was approximately $25.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...